Explore Synthego's high-fidelity novel nuclease, hfCas12Max and how it can accelerate the development of CRISPR-based therapeutics.

In the rapidly evolving field of CRISPR-based therapeutics, navigating the SpCas9 IP landscape presents a formidable challenge for researchers seeking a nuclease suitable for their therapeutic development. To overcome these challenges and to make CRISPR more accessible, our high-fidelity novel nuclease, hfCas12Max, and high-quality CRISPR guide RNA (gRNA) are accelerating CRISPR-based therapeutic development. Characterized by its high fidelity (high editing efficiency and low off-target editing) and broad PAM sequence recognition while maintaining binding specificity across a wide variety of cell types, hfCas12Max is the nuclease you need to achieve success in your experiments developing your CRISPR-based therapeutic.

Explore hfCas12Max data including:

  • High editing efficiency and cell viability across a wide range of cell types
  • Off-target analysis
  • PAM sequence recognition comparison to other Cas nucleases
  • CRISPR knock-in editing efficiency

Download Now!